Skip to main content
padlock icon - secure page this page is secure

Recent Developments on Multi-Target-Directed Tacrines for Alzheimer's Disease. I. The Pyranotacrines

Buy Article:

$68.00 + tax (Refund Policy)

Tacrine was the first drug to display beneficial effects on cognitive impairment of Alzheimer Disease (AD) patients. Unfortunately, many treated patients displayed related hepatotoxicity, and hence this drug was withdrawn. Notwithstanding, recent efforts have been directed to design small tacrine analogues targeting the underlying pathogenic mechanisms of AD. In this context, we have developed a number of pyranotacrines by changing the benzene fused ring in tacrine by a 4Hpyran. Based on this strategy, in this account we will show the tacrine analogues that we have designed, synthesized and evaluated as potential multipotent agents for AD in the last years. We have demonstrated that this approach is possible, and that a number of readily available tacrine analogues show cholinesterase inhibition power, as well as other pharmacological properties, such as calcium channel blockade, antioxidant properties, neuroprotection, Aβ-amyloid inhibition aggregation capacity, etc., making them suitable multipotent molecules for further development for the potential treatment of AD.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Acetylcholinesterase inhibitors; Alzheimer's disease; Butyrylcholinesterase inhibitors; Multi-Target-Directed Ligands; Neuroprotection; Pyranotacrines; Tacrine

Document Type: Review Article

Publication date: December 1, 2017

This article was made available online on January 22, 2018 as a Fast Track article with title: "Recent Developments on Multi-Target-Directed Tacrines for Alzheimer’s Disease. I. The Pyranotacrines".

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more